Cover - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
Cover - USD ($) $ / shares in Units, $ in Millions	Dec. 31, 2025	Mar. 23, 2026	Jun. 30, 2024
Cover [Abstract]
Document Type	10-K/A
Amendment Flag	true
Amendment Description	This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K of RenovoRx, Inc. (“Company”) for the year ended December 31, 2025 filed with the Securities and Exchange Commission (the “Commission”) on March 30, 2026 (the “Original Filing”). In response to a comment letter from the Commission staff, this Amendment is being filed solely to revise (i) Part I, Item 1A. “Risk Factors” (“Item 1A”) to revise certain risk factors disclosures relating to previously identified material weaknesses in internal control over financial reporting (which were remediated as of December 31, 2025) and (ii) the Company’s disclosures under Part II, Item 9A. “Controls and Procedures” (“Item 9A”) by adding additional disclosure regarding management’s assessments and conclusions of the Company’s internal control over financial reporting as of December 31, 2025, which was not included in Item 9A in the Original Filing. Management’s assessment, as reported in the Original 10-K, that such internal control over financial reporting was effective at December 31, 2025 remain unchanged. The revised risk factors are captioned “We have previously identified material weaknesses in our internal control over financial reporting. Failure to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock. If our internal controls are not effective, we may not be able to accurately report our financial results or prevent fraud” and “We previously found our disclosure controls and procedures were not effective, and there is a risk that we may do so again, which could have an adverse effect on our company.” In accordance with Rule 12b-15 of the Securities and Exchange Act of 1934, as amended, this Amendment amends and restates Item 1A and Item 9A of the Original Filing in their entirety, but solely for purposes of the above described limited revisions. In addition, as required by Rule 12b-15, new certifications by the Company’s principal executive officer and principal financial officer are filed as exhibits to this Amendment. Except as described above, no other changes have been made to the Original Filing. This Amendment continues to speak as of the date of the Original Filing, and the Company has not updated the disclosures contained therein to reflect any events that occurred subsequent to the date of the Original Filing. Accordingly, this Amendment should be read together with the Original Filing.
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2025
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--12-31
Entity File Number	001-40738
Entity Registrant Name	RENOVORX, INC.
Entity Central Index Key	0001574094
Entity Tax Identification Number	27-1448452
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2570 West El Camino Real
Entity Address, Address Line Two	Suite 640
Entity Address, City or Town	Mountain View
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94040
City Area Code	650
Local Phone Number	284-4433
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	RNXT
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 26.6
Entity Common Stock, Shares Outstanding		45,052,706
Documents Incorporated by Reference	None
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Listing, Par Value Per Share	$ 0.0001

RenovoRx, Inc. 10-K/A